ReviewFrontiers in oncology2026
Novel approaches for separating graft-versus-leukemia effects from graft-versus-host disease.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Paeoniflorin prevents acute graft-versus-host disease while preserving graft-versus-tumor effects.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Allogeneic hematopoietic cell transplantation (allo-HCT) is a curative therapy for various hematologic malignancies. Separation of graft-versus-leukemia (GVL) effects from graft-versus-host disease (GVHD) remains one of the central challenges in allo-HCT. However, relapse after allo-HCT remains associated with poor prognosis, and effective strategies that preserve graft-versus-leukemia (GVL) effects while preventing graft-versus-host disease (GVHD) are still lacking. Recent advances have revealed that post-transplant relapse is driven by diverse mechanisms, including leukemia-intrinsic immune escape, donor T-cell exhaustion, and persistence of leukemia stem cells. Emerging therapeutic strategies, such as selective modulation of T-cell trafficking and enhancement of tissue tolerance, are promising approaches to ameliorate GVHD without attenuating GVL effects. Additional approaches including cellular therapies, selective immune modulation, and restoration of leukemia immunogenicity are also being actively explored. Furthermore, restoration of leukemia immunogenicity and targeted elimination of leukemia stem cells are expected to provide new opportunities to prevent relapse without aggravating GVHD. In addition, approaches that reshape the tumor immune microenvironment or modulate T-cell exhaustion may further strengthen GVL activity while limiting harmful alloreactivity. These developments suggest that the long-considered difficult goal of separating GVHD from GVL effects may become achievable in the near future. In this review, we provide an overview of novel therapeutic targets aimed at achieving the separation of GVHD and GVL, with a particular focus on findings related to acute myeloid leukemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.